Section Arrow
ONC.NASDAQ
- BeOne Medicines Ltd
Quotes are at least 15-min delayed:2025/07/21 07:03 EDT
Pre Market
Last
 287.99
-6.56 (-2.23%)
Bid
282
Ask
291.6
High 293.8 
Low 287.99 
Volume 560 
Regular Hours
Last
 294.55
+4.2 (+1.45%)
Day High 
300 
Prev. Close
290.35 
1-M High
298 
Volume 
893.53K 
Bid
282
Ask
291.6
Day Low
293.51 
Open
297.5 
1-M Low
239.25 
Market Cap 
31.42B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 258.17 
20-SMA 255.01 
50-SMA 249.1 
52-W High 300 
52-W Low 152.81 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.64/6.63
Enterprise Value
31.63B
Balance Sheet
Book Value Per Share
32.34
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
238.39M
Operating Revenue Per Share
17.01
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2.04 -0.24 -10.53%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.08 -0.995 -7.07%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0473 -0.0004 -0.84%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.19 +0.35 +5.99%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.1 +0.18 +3.04%
Quotes are at least 15-min delayed:2025/07/21 07:03 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies witha contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.